At its H1 2026 results briefing, Botuo Biotech said it will continue to raise R&D spending in its core business, advancing innovative product development and commercialization to enhance product competitiveness. The company said it will selectively p

2026-09-07

At its H1 2026 results briefing, Botuo Biotech said it will continue to raise R&D spending in its core business, advancing innovative product development and commercialization to enhance product competitiveness. The company said it will selectively pursue acquisitions and other investments to expand into the healthcare and wellness sector.